Clinical Trial Detail

NCT ID NCT04071223
Title Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

chromophobe renal cell carcinoma

clear cell renal cell carcinoma

papillary renal cell carcinoma

renal cell carcinoma

collecting duct carcinoma

Therapies

Cabozantinib + Radium Ra 223 dichloride

Cabozantinib

Age Groups: adult senior

No variant requirements are available.